Resources Category: Patients

In this video patients share their experiences of living with AL and ATTR amyloidosis. They discuss the needs for research, clinical trials and their dreams. This video was shared with the FDA in 2015 during ARC's Patient Focused Drug Development Meeting.

This webinar provides information on navigating work and amyloidosis. Covering the laws that can protect you as you work through treatment, taking job protected time off if necessary, and how to pay for time off. This webinar will be hosted on 7th November at 11am EST. Use link below to register.

This webinar provides helpful information on what to consider when choosing a healthcare insurance plan. This webinar was hosted by Triage Cancer and funded by Alnylam Pharmaceuticals.

An informative webinar, led by speaker Beth Halpern, Partner at Hogan Lovells US LLP, providing a detailed explanation of the different pathways available to support patients in accessing these new treatments

Finding the best amyloidosis care is not easy. ARC created My Amyloidosis Pathfinder (MAP) to help you discover, learn about, and contact treatment centers and clinical trials that are right for you. By answering our short questionnaire, MAP is able to match you to centers and trials specific to your condition.

Have you ever wondered where medicines come from? Or how medicines are tested for efficacy and safety before becoming commercially available? Find out what clinical trials are and the purpose of this rigorous testing process. This video was produced as part of the Americans for Cures Foundation's Report Back to the Public.

This video, presented by Dr. Martha Grogan, a leading amyloidosis cardiologist, provides an in depth overview regarding the treatment options for patients who have cardiac amyloidosis.

This video, presented by Dr. Morie Gertz, a leading amyloidosis hematologist, provides an overview of: what amyloidosis is, symptoms of amyloidosis, the advantages that Mayo Clinic provides for patients, and, how Mayo's research and resources are shaping its treatment of amyloidosis.